References
- Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M. A., Prieto-Sanchez, R. M., Barba, I., Martinez-Saez, E., Prudkin, L. et al. (2010). TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell., 18 (6), 655–668.10.1016/j.ccr.2010.10.023
- Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., Itinteang, T. (2016). Cancer stem cell hierarchy in glioblastoma multi-forme. Front Surg., 3, 21.
- Brown, D. V., Daniel, P. M., D’Abaco, G. M., Gogos, A., Ng, W., Morokoff, A. P., Mantamadiotis, T. (2015). Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme. Oncotarget, 6 (8), 6267–6280.10.18632/oncotarget.3365
- Cai, J., Zhu, P., Zhang, C., Li, Q., Wang, Z., Li, G., Wang, G., Yang, P., Li, J., Han, B., Jiang, C., Sun, Y., Jiang, T. (2016). Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget, 7 (13), 16384–16395.10.18632/oncotarget.7650
- Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M. R., Kelsey, K. T., Wiencke, J. K. (2011). DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst., 103 (2), 143–153.10.1093/jnci/djq497
- Cohen, A., Holmen, S., Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep., 13 (5), 345–345.10.1007/s11910-013-0345-4
- Dzwonek, J., Wilczynski, G. M. (2015). CD44: Molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci., 9, 175.10.3389/fncel.2015.00175
- Gravendeel, L. A., Kloosterhof, N. K., Bralten, L. B., van Marion, R., Dubbink, H. J., Dinjens, W., Bleeker, F. E., Hoogenraad, C. C., Michiels, E., Kros, J. M., van den Bent, M., Smitt, P. A., French, P. J. (2010). Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum. Mutat., 31 (3), E1186–1199.
- Jijiwa, M., Demir, H., Gupta, S., Leung, C., Joshi, K., Orozco, N., Huang, T., Yildiz, V. O., Shibahara, I., de Jesus, J. A., Yong, W. H., Mischel, P. S., Fernandez, S., Kornblum, H. I., Nakano, I. (2011). CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One., 6 (9), e24217.10.1371/journal.pone.0024217
- Juratli, T. A., Kirsch, M., Robel, K., Soucek, S., Geiger, K., von Kummer, R., Schackert, G., Krex, D. (2012). IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J. Neurooncol., 108 (3), 403–410.10.1007/s11060-012-0844-1
- Kaaijk, P., Pals, S. T., Morsink, F., Bosch, D. A., Troost, D. (1997). Differential expression of CD44 splice variants in the normal human central nervous system. J. Neuroimmunol., 73 (1–2), 70–76.10.1016/S0165-5728(96)00167-1
- Klank, R. L., Decker Grunke, S. A., Bangasser, B. L., Forster, C. L., Price, M. A., Odde, T. J., SantaCruz, K. S., Rosenfeld, S. S., Canoll, P., Turley, E. A., McCarthy, J. B., Ohlfest, J. R., Odde, D. J. (2017). Biphasic dependence of glioma survival and cell migration on CD44 expression level. Cell Rep., 18 (1), 23–31.10.1016/j.celrep.2016.12.024549814928052252
- Le Mercier, M., Hastir, D., Moles Lopez, X., De Neve, N., Maris, C., Trepant, A. L., Rorive, S., Decaestecker, C., Salmon, I. (2012). A simplified approach for the molecular classification of glioblastomas. PLoS One, 7 (9), e45475.10.1371/journal.pone.0045475
- Liu, Y., Han, S. S., Wu, Y., Tuohy, T. M., Xue, H., Cai, J., Back, S. A., Sherman, L. S., Fischer, I., Rao, M. S. (2004). CD44 expression identifies astrocyte-restricted precursor cells. Dev. Biol., 276 (1), 31–46.10.1016/j.ydbio.2004.08.018
- Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K. (2016). Astrocytic tumours. In: WHO Classification of Tumours of the Central Nervous System (Fourth Edition). WHO Press, Lyon, pp. 13–53.
- Malik, N., Wang, X., Shah, S., Efthymiou, A. G., Yan, B., Heman-Ackah, S., Zhan, M., Rao, M. (2014). Comparison of the gene expression profiles of human fetal cortical astrocytes with pluripotent stem cell derived neural stem cells identifies human astrocyte markers and signaling pathways and transcription factors active in human astrocytes. PLoS One, 9 (5), e96139.10.1371/journal.pone.0096139
- Mooney, K. L., Choy, W., Sidhu, S., Pelargos, P., Bui, T. T., Voth, B., Barnette, N., Yang, I. (2016). The role of CD44 in glioblastoma multiforme. J.Clin. Neurosci., 34, 1–5.10.1016/j.jocn.2016.05.012
- Motomura, K., Natsume, A., Watanabe, R., Ito, I., Kato, Y., Momota, H., Nishikawa, R., Mishima, K., Nakasu, Y., Abe, T., Namba, H., Nakazato, Y., Tashiro, H., Takeuchi, I., Mori, T., Wakabayashi, T. (2012). Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci., 103 (10), 1871–1879.10.1111/j.1349-7006.2012.02377.x
- Naor, D., Sionov, R. V., Ish-Shalom, D. (1997). CD44: Structure, function, and association with the malignant process. Adv. Cancer Res., 71, 241–319.10.1016/S0065-230X(08)60101-3
- Naruse, M., Shibasaki, K., Yokoyama, S., Kurachi, M., Ishizaki, Y. (2013). Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum. PLoS One., 8 (1), e53109.10.1371/journal.pone.0053109353776923308146
- Nobusawa, S., Watanabe, T., Kleihues, P., Ohgaki, H. (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res., 15 (19), 6002–6007.10.1158/1078-0432.CCR-09-071519755387
- Ohgaki, H., Kleihues, P. (2013). The definition of primary and secondary glioblastoma. Clin. Cancer Res., 19 (4), 764–772.10.1158/1078-0432.CCR-12-300223209033
- Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L. et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321 (5897), 1807–1812.
- Petrey, A. C., de la Motte, C. A. (2014). Hyaluronan, a crucial regulator of inflammation. Front Immunol., 5, 101.10.3389/fimmu.2014.00101394914924653726
- Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., Williams, P. M., Modrusan, Z., Feuerstein, B. G., Aldape, K. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9 (3), 157–173.10.1016/j.ccr.2006.02.01916530701
- Pietras, A., Katz, A. M., Ekstrom, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., Holland, E. C. (2014). Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell., 14 (3), 357–369.10.1016/j.stem.2014.01.005399904224607407
- Popova, S. N., Bergqvist, M., Dimberg, A., Edqvist, P. H., Ekman, S., Hesselager, G., Ponten, F., Smits, A., Sooman, L., Alafuzoff, I. (2014). Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology, 64 (3), 365–379.10.1111/his.12252467047524410805
- Prochazka, L., Tesarik, R., Turanek, J. (2014). Regulation of alternative splicing of CD44 in cancer. Cell Signal., 26 (10), 2234–2239.10.1016/j.cellsig.2014.07.01125025570
- Ranuncolo, S. M., Ladeda, V., Specterman, S., Varela, M., Lastiri, J., Morandi, A., Matos, E., Bal de Kier Joffe, E., Puricelli, L., Pallotta, M. G. (2002). CD44 expression in human gliomas. J. Surg. Oncol., 79 (1), 30–35.10.1002/jso.1004511754374
- Sahlberg, S. H., Spiegelberg, D., Glimelius, B., Stenerlow, B., Nestor, M. (2014). Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One., 9 (4), e94621.10.1371/journal.pone.0094621399740324760019
- Shankar, A., Kumar, S., Iskander, A., Varma, N. R. S., Janic, B., deCarvalho, A., Mikkelsen, T., Frank, J. A., Ali, M. M., Knight, R. A., Brown, S., Arbab, A. S. (2014). Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo. Chin J. Cancer, 33 (3), 148–158.10.5732/cjc.013.10095396621524016393
- Si, D., Yin, F., Peng, J., Zhang, G. (2020). High expression of CD44 predicts a poor prognosis in glioblastomas. Cancer Manag. Res., 12, 769–775.10.2147/CMAR.S233423700685932099472
- Sosunov, A. A., Wu, X., Tsankova, N. M., Guilfoyle, E., McKhann, G. M., Goldman, J. E. (2014). Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. J. Neurosci.,34 (6), 2285–2298.10.1523/JNEUROSCI.4037-13.2014391387224501367
- Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P. et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17 (1), 98–110.10.1016/j.ccr.2009.12.020281876920129251
- Wang, C., Wang, Z., Chen, C., Fu, X., Wang, J., Fei, X., Yan, X., Xu, R. (2020). A small-molecule CD44 dimerizing inhibitor for glioblastoma treatment. Brit. J. Pharmacol., 11 (19), 491–498.
- Ward, P. S., Cross, J. R., Lu, C., Weigert, O., Abel-Wahab, O., Levine, R. L., Weinstock, D. M., Sharp, K. A., Thompson, C. B. (2012). Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogen,31 (19), 2491–2498.10.1038/onc.2011.416327113321996744
- Xu, H., Tian, Y., Yuan, X., Wu, H., Liu, Q., Pestell, R. G., Wu, K. (2015). The role of CD44 in epithelial–mesenchymal transition and cancer development. OncoTargets Ther.,8, 3783–3792.
- Xu, Y., Stamenkovic, I., Yu, Q. (2010). CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res., 70 (6), 2455–2464.10.1158/0008-5472.CAN-09-2505284007320197461
- Ylagan, L. R., Quinn, B. (1997). CD44 expression in astrocytic tumors. Mod. Pathol., 10 (12), 1239–1246.